EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Remibrutinib (Rhapsido®), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticaria

Abdusemi Abduweli, Longqin Hu iD

Medicinal Chemistry Research · 02.11.2026

DOI: 10.1007/s00044-026-03634-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Chemistry Research, online erschienen am 02.11.2026. Verfasst von Abdusemi Abduweli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remibrutinib (Rhapsido ® ) is a selective, orally bioavailable covalent inhibitor of Bruton’s tyrosine kinase (BTK), approved in 2025 for the treatment of adult chronic spontaneous urticaria (CSU) uncontrolled by H 1 -antihistamines. By blocking BTK, it suppresses signaling pathways driving mast cell, basophil, and B-cell activation in immune-mediated disease. This review traces remibrutinib’s journey from target validation to market approval, detailing the structure–activity relationships that optimized early CGI-560 and CGI-1746 scaffolds into pyrrolopyrimidine and 6-aminopyrimidine series, as well as the process chemistry redesign for commercial synthesis. By covalently capturing BTK in its inactive conformation, remibrutinib achieves exceptional kinase selectivity. This translates into rapid symptom control, convenient oral administration as an alternative to injectable biologics, and a favorable safety profile where mild mucocutaneous bleeding is the primary mechanism-based risk. Remibrutinib is also in late-stage development for other chronic, non-lethal inflammatory conditions including chronic inducible urticaria, hidradenitis suppurativa, Sjögren disease, and multiple sclerosis.

Schlagwörter

Stichwörter der Autor:innen

Autoimmune diseasesBruton’s tyrosine kinaseChronic spontaneous urticariaCovalent inhibitorRemibrutinib

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
  • Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. longhu@pharmacy.rutgers.edu.
  • Rutgers Cancer Institute, 195 Little Albany Street, New Brunswick, NJ, 08903, USA. longhu@pharmacy.rutgers.edu.

ORCID-Profile: Longqin Hu

Zitieren

APA

Abduweli, A., & Hu, L. (2026). Remibrutinib (Rhapsido®), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticaria. Medicinal Chemistry Research. https://doi.org/10.1007/s00044-026-03634-2

Vancouver

Abduweli A, Hu L. Remibrutinib (Rhapsido®), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticaria. Medicinal Chemistry Research. 2026. doi:10.1007/s00044-026-03634-2

BibTeX
@article{Abduweli2026,
  author = {Abduweli, Abdusemi and Hu, Longqin},
  title = {Remibrutinib (Rhapsido®), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticaria},
  journal = {Medicinal Chemistry Research},
  year = {2026},
  doi = {10.1007/s00044-026-03634-2}
}
Kostenlos starten →